

Loss of skeletal muscle during neoadjuvant chemotherapy in ovarian cancer patients

Journal of Cachexia, Sarcopenia and Muscle
7, 458-466

DOI: [10.1002/jcsm.12107](https://doi.org/10.1002/jcsm.12107)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer". <i>Journal of Clinical Oncology</i> , 2016, 34, 3816-3817.	0.8	5
2	Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 458-466.	2.9	161
3	Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. <i>Journal of Cancer Survivorship</i> , 2017, 11, 339-349.	1.5	96
4	The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 310-317.	2.9	141
5	Impact of sarcopenia in the management of urological cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 455-466.	1.1	32
6	A comparison of research into cachexia, wasting and related skeletal muscle syndromes in three chronic disease areas. <i>International Journal of Cardiology</i> , 2017, 235, 33-36.	0.8	6
7	The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. <i>European Journal of Surgical Oncology</i> , 2017, 43, 717-724.	0.5	81
8	Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 630-638.	2.9	144
9	Panoramic ultrasound: a novel and valid tool for monitoring change in muscle mass. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 475-481.	2.9	60
10	An analysis of the types of recently published research in the field of cachexia. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1759-1773.	0.8	3
11	Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3741-3747.	0.7	44
12	Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 555-561.	1.1	29
13	ERAS: Improving outcome in the cachectic HPB patient. <i>Journal of Surgical Oncology</i> , 2017, 116, 617-622.	0.8	12
14	Sarcopenia in Advanced Serous Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 223-232.	1.2	56
15	A Physiological Profile of Ovarian Cancer Survivors to Inform Tailored Exercise Interventions and the Development of Exercise Oncology Guidelines. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1560-1567.	1.2	8
16	Casting the net broader to confirm our imaginations: the long road to treating wasting disorders. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 870-880.	2.9	19
17	Muscle wasting and sarcopenia in heart failure and beyond: update 2017. <i>ESC Heart Failure</i> , 2017, 4, 492-498.	1.4	168
18	Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival. <i>Supportive Care in Cancer</i> , 2017, 25, 795-800.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. , 2017, 8, 677.		31
20	Insulin resistance and body composition in cancer patients. <i>Annals of Oncology</i> , 2018, 29, ii18-ii26.	0.6	99
21	Activity Behaviors and Physiological Characteristics of Women With Advanced-Stage Ovarian Cancer: A Preliminary Cross-sectional Investigation. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 604-613.	1.2	7
22	Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice. <i>Cancer Biology and Therapy</i> , 2018, 19, 87-96.	1.5	10
23	Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. <i>Clinical Radiology</i> , 2018, 73, 505.e1-505.e8.	0.5	13
24	Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1229-1236.	0.7	39
25	Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 315-325.	2.9	147
26	Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 156.e9-156.e16.	0.8	15
27	Impact of body composition on outcome in patients with early breast cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 861-868.	1.0	107
28	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 703-712.	0.9	39
29	Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 95-105.	1.1	37
30	Contemporary publication patterns in the <i>Journal of Cachexia, Sarcopenia and Muscle</i> by type and subspecialty: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1192-1195.	2.9	1
31	Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 420-426.	0.5	108
32	Targeting IL-1 β in cancer cachexia: a narrative review. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 453-459.	0.5	28
33	Omega-3 and omega-3/curcumin-enriched fruit juices decrease tumour growth and reduce muscle wasting in tumour-bearing mice. <i>JCSM Rapid Communications</i> , 2018, 1, 1-10.	0.6	5
34	Skeletal muscle wasting in chronic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 1099-1107.	1.4	91
35	Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 411-418.	0.2	18
36	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. <i>Oncotarget</i> , 2018, 9, 14005-14034.	0.8	71

#	ARTICLE	IF	CITATIONS
37	Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 793-801.	2.9	5
38	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 745-755.	1.7	14
39	Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5028-5036.	3.2	58
40	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 54-66.	2.0	34
41	Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue. <i>Frontiers in Pharmacology</i> , 2018, 9, 452.	1.6	16
42	Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. <i>BMC Cancer</i> , 2018, 18, 756.	1.1	44
43	Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 3372-3379.	0.7	58
44	Screening for low muscularity in colorectal cancer patients: a valid, clinic-friendly approach that predicts mortality. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 898-908.	2.9	37
45	Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 685-700.	2.9	74
46	A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. <i>Proceedings of the Nutrition Society</i> , 2018, 77, 135-151.	0.4	62
47	L-carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922.	2.0	67
48	Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1-29.	1.1	20
49	Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1165-1174.	2.9	108
50	Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. <i>Nutrition</i> , 2019, 67-68, 110539.	1.1	106
51	The Journal of Cachexia, Sarcopenia and Muscle in 2019. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 715-720.	2.9	1
52	Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2019, 120, 107-113.	1.3	22
53	Change in Skeletal Muscle Following Resection of Stage III Colorectal Cancer is Predictive of Poor Survival: A Cohort Study. <i>World Journal of Surgery</i> , 2019, 43, 2518-2526.	0.8	20
54	Muscle mass loss in patients with metastatic breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 201-206.	0.8	8

#	ARTICLE	IF	CITATIONS
56	Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 860-871.	2.9	42
57	Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 814-826.	2.9	48
58	Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 216-222.e5.	0.9	21
59	Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 760.	1.8	19
60	The difference in referencing in <sc>Web of Science</sc>, <sc>Scopus</sc>, and <sc>Google Scholar</sc>. <i>ESC Heart Failure</i> , 2019, 6, 1291-1312.	1.4	25
61	The <i>Journal of Cachexia, Sarcopenia and Muscle</i> stays the frontâ€runner in geriatrics and gerontology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1151.	2.9	3
62	Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. <i>Surgery</i> , 2019, 165, 329-336.	1.0	26
63	Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. <i>British Journal of Sports Medicine</i> , 2019, 53, 812-812.	3.1	67
64	Loss of psoas major muscle volume during systemic chemotherapy is related to worse prognosis in testicular cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 183-189.	0.6	7
65	Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Clinical Nutrition</i> , 2020, 39, 820-828.	2.3	32
66	Sarcopenia, but not frailty, predicts early mortality and adverse events after emergent surgery for metastatic disease of the spine. <i>Spine Journal</i> , 2020, 20, 22-31.	0.6	65
67	Deep learning for automated segmentation of pelvic muscles, fat, and bone from CT studies for body composition assessment. <i>Skeletal Radiology</i> , 2020, 49, 387-395.	1.2	59
68	Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 111, 267-277.	0.7	11
69	Association between low muscle mass and survival in incurable cancer patients: A systematic review. <i>Nutrition</i> , 2020, 72, 110695.	1.1	19
70	Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer. <i>Nutrition</i> , 2020, 72, 110642.	1.1	21
71	Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 914-920.	0.7	19
72	Muscle wasting associated co-morbidities, rather than sarcopenia are risk factors for hospital mortality in critical illness. <i>Journal of Critical Care</i> , 2020, 56, 31-36.	1.0	33
73	Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. <i>Liver International</i> , 2020, 40, 1178-1188.	1.9	45

#	ARTICLE	IF	CITATIONS
74	Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 2662-2671.	0.6	11
75	The Association Between Computed Tomography-Defined Sarcopenia and Outcomes in Adult Patients Undergoing Radiotherapy of Curative Intent for Head and Neck Cancer: A Systematic Review. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 1330-1347.e8.	0.4	39
76	No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. <i>Gynecologic Oncology</i> , 2020, 159, 706-711.	0.6	12
77	Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. <i>BJS Open</i> , 2020, 4, 847-854.	0.7	18
78	A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1791-1797.	1.2	18
79	Quantitative Imaging of Body Composition. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 375-385.	0.4	12
80	Low skeletal muscle mass and postoperative morbidity in surgical oncology: a systematic review and meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 636-649.	2.9	64
81	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	1.2	42
82	Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. <i>Gynecologic Oncology</i> , 2020, 156, 695-700.	0.6	25
83	Chemotherapy-Induced Sarcopenia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 7.	1.3	61
84	Impact of intramuscular adipose tissue content on short- and long-term outcomes of hepatectomy for colorectal liver metastasis: a retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 68.	0.8	24
85	The Impact of Sarcopenia and Low Muscle Attenuation on Overall Survival in Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 3553-3564.	0.7	21
86	Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. <i>Proceedings of the Nutrition Society</i> , 2021, 80, 73-91.	0.4	15
87	Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation. <i>Gynecologic Oncology</i> , 2021, 160, 40-44.	0.6	12
88	Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study. <i>Journal of Human Nutrition and Dietetics</i> , 2021, 34, 585-594.	1.3	11
89	The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer. <i>Anticancer Research</i> , 2021, 41, 9-20.	0.5	8
90	Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia. <i>FASEB Journal</i> , 2021, 35, e21335.	0.2	20
91	Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on long-term outcomes after gastrectomy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 61-69.	0.7	4

#	ARTICLE	IF	CITATIONS
92	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. <i>Nutrients</i> , 2021, 13, 960.	1.7	16
93	Deep Learning Automated Segmentation for Muscle and Adipose Tissue from Abdominal Computed Tomography in Polytrauma Patients. <i>Sensors</i> , 2021, 21, 2083.	2.1	20
94	Systematic review and meta-analysis of lean mass and mortality: Rationale and study description. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, S3-S12.	0.7	9
95	Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: A longitudinal study. <i>Radiotherapy and Oncology</i> , 2021, 158, 83-89.	0.3	15
96	Intramuscular adipose tissue at level Th12 is associated with survival in COVID-19. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 823-827.	2.9	15
97	A novel model with nutrition-related parameters for predicting overall survival of cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 6721-6730.	1.0	2
98	Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 983-992.	2.9	9
99	The impact of body composition on treatment in ovarian cancer: a current insight. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1065-1074.	1.3	11
100	Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers. <i>Molecular and Clinical Oncology</i> , 2021, 15, 177.	0.4	10
101	Bioelectrical Impedance Analysis and Mid-Upper Arm Muscle Circumference Can Be Used to Detect Low Muscle Mass in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2350.	1.7	12
102	CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients. <i>Nutrients</i> , 2021, 13, 2647.	1.7	25
103	Muscle hypertrophy in cancer patients and survivors via strength training. A meta-analysis and meta-regression. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103371.	2.0	25
104	Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study. <i>Clinical Nutrition</i> , 2021, 40, 4980-4987.	2.3	7
105	Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. <i>European Journal of Radiology</i> , 2021, 145, 109943.	1.2	39
106	Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 719643.	1.8	19
107	Physical Fitness and Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: An Observational Study. <i>Rehabilitation Oncology</i> , 2021, 39, E73-E82.	0.2	1
108	The influence process of sarcopenia on female cancer: A systematic review and meta-analysis. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 4403-4413.	0.6	6
109	The Cachexia Syndrome in Pancreatic Cancer. , 2021, , 235-250.		0

#	ARTICLE	IF	CITATIONS
110	Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors. <i>Cancer Control</i> , 2021, 28, 107327482110384.	0.7	9
111	Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 534-546.	2.9	54
112	Determinants of adherence to physical cancer rehabilitation guidelines among cancer patients and cancer centers: a cross-sectional observational study. <i>Journal of Cancer Survivorship</i> , 2021, 15, 163-177.	1.5	9
113	Rationale and study protocol of the Physical Activity and Dietary intervention in women with OVArian cancer (PADOVA) study: a randomised controlled trial to evaluate effectiveness of a tailored exercise and dietary intervention on body composition, physical function and fatigue in women with ovarian cancer undergoing chemotherapy. <i>BMI Open</i> , 2020, 10, e036854.	0.8	18
114	Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 654-663.	1.2	22
115	Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. <i>Oncotarget</i> , 2018, 9, 25714-25722.	0.8	42
116	Sarcopenia in Ovarian Cancer Patients, Oncologic Outcomes Revealing the Importance of Clinical Nutrition: Review of Literature. <i>Current Pharmaceutical Design</i> , 2019, 25, 2480-2490.	0.9	19
117	Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. <i>American Journal of Surgery</i> , 2022, 223, 927-932.	0.9	4
118	Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. <i>European Journal of Surgical Oncology</i> , 2022, 48, 896-902.	0.5	7
119	Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. <i>Acta Oncol3gica</i> , 2021, 60, 1611-1620.	0.8	10
121	Whole-Body Vibration Exercise in Cancer. , 2020, , 381-396.		1
122	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. <i>American Journal of Cancer Research</i> , 2017, 7, 1107-1135.	1.4	15
123	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	0
124	Computed Tomography-Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 718815.	1.3	14
125	Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2022, 97, 106206.	1.1	12
126	Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study. <i>Anticancer Research</i> , 2022, 42, 947-954.	0.5	3
127	Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study). <i>BMJ Open</i> , 2022, 12, e054091.	0.8	7
128	Pre-treatment sarcopenic assessments as a prognostic factor for gynaecology cancer outcomes: systematic review and meta-analysis. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 1513-1527.	1.3	8

#	ARTICLE	IF	CITATIONS
129	Prevalence of computed tomography-based sarcopenia and the prognostic value of skeletal muscle index and muscle attenuation amongst women with epithelial ovarian malignancy: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1441-1454.	0.5	8
130	Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study. <i>Gynecologic Oncology</i> , 2022, 165, 619-628.	0.6	4
131	The comparison of the prognostic value of scored patient generated subjective global assessment and Computed Tomography measured sarcopenia in patients with gynecological cancer. <i>Clinical Nutrition ESPEN</i> , 2022, 48, 253-258.	0.5	1
132	Effect of exercise on body composition among women with ovarian cancer. <i>Journal of Cancer Survivorship</i> , 2023, 17, 1386-1396.	1.5	7
133	Ovarian cancer ascites induces skeletal muscle wasting <i>in vitro</i> and reflects sarcopenia in patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 311-324.	2.9	8
134	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	3
135	Ingestão Alimentar de Mulheres com Tumores Ginecológicos em Tratamento Oncológico: Revisão Integrativa da Literatura. <i>Revista Brasileira De Cancerologia</i> , 2022, 68, .	0.0	0
136	The prevalence of sarcopenia amongst non-small cell lung cancer patients, assessed using computed tomography, prior to treatment in a South African setting. <i>South African Journal of Oncology</i> , 0, 6, .	0.1	0
137	Effect of Muscle Loss but Not Fat Loss during Primary Debulking Surgery and Chemotherapy on Prognosis of Patients with Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3184.	1.0	3
138	Acute skeletal muscle loss in SARS-CoV-2 infection contributes to poor clinical outcomes in COVID-19 patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2436-2446.	2.9	17
139	Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 4567.	1.7	2
140	Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy. <i>Anticancer Research</i> , 2022, 42, 4887-4893.	0.5	1
141	Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance. <i>Cells</i> , 2022, 11, 3305.	1.8	3
142	Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
143	Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer. <i>Nutrients</i> , 2022, 14, 5183.	1.7	0
144	Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
145	High visceral fat-to-muscle ratio is an independent factor that predicts worse overall survival in patients with primary epithelial ovarian, fallopian tube, and peritoneal cancer. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	4
146	Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy. , 2023, 36, .		0

#	ARTICLE	IF	CITATIONS
147	Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023, 14, 697-705.	2.9	9
148	Association between sarcopenia and survival in patients with gynecologic cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
150	Efficacy of exercise interventions for women during and after gynaecological cancer treatment – a systematic scoping review. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	2
154	Ganzkörpervibrationstraining bei Krebs. , 2023, , 421-438.		0